← Back to all trials
Enrolling By Invitation
NCT06896110
Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
Conditions: Glioblastoma (GBM), Diffuse Midline Glioma (DMG), Astrocytoma, IDH-Mutant, Grade 4, Diffuse Hemispheric Glioma, H3 G34-Mutant, Gliosarcoma of Brain
Sex: All
Ages: 13 Years – N/A
Healthy volunteers: No
Phase: PHASE1
Enrollment: 34
Sponsor: Andrew P. Groves
Location: Holden Comprehensive Cancer Center Iowa City Iowa
Summary
This is a single-arm open-label phase 1 dose escalation/expansion trial assessing the safety and efficacy of concurrent intrathecal azacitidine and intrathecal nivolumab in recurrent high-grade glioma.
Eligibility Criteria
INCLUSION CRITERIA
1. For patients age ≥ 18: Able and willing to provide written informed consent
2. For patients aged 13-17: Parent/guardian of adolescent patient must have the ability to provide written informed consent. Adolescent patients must have the ability to provide written informed assent.
3. Stated willingness to comply with all trial procedures and availability for the duration of the trial
4. Histologically confirmed diagnosis of World Health Organization Grade IV high-grade glioma. Eligible diagnoses include: Glioblastoma (IDH-wildtype), Gliosarcoma, Diffuse Midline Glioma (H3 K27-altered), diffuse hemispheric glioma (H3 G34-mutant), diffuse pediatric-type high-grade glioma (H3 and IDH-wildtype), Astrocytoma IDH-mutant (Grade 4)
5. Previous first-line treatment with at least radiotherapy (and temozolomide in the case of glioblastoma or astrocytoma IDH-mutant (grade 4))
6. Documented recurrence by diagnostic biopsy or contrast-enhanced magnetic resonance imaging (MRI) per RANO 2.0 criteria
7. At least one measurable lesion per RANO 2.0 meeting the following criteria: Contrast-enhancing or non-enhancing lesions with clearly defined margins by MRI Scan, with both perpendicular diameters on a single slice of at least 10 mm, visible on two or more slices that are preferably, at most, 3 mm apart with 0-mm interslice gap.
8. Age ≥ 13
9. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (age ≥ 16) or Lansky of ≥ 60 (age \
Source: ClinicalTrials.gov (NCT06896110). StuddyBuddy aggregates publicly available trial information.